Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Sage Therapeutics, Inc. - Common Stock (NQ:SAGE)

8.680 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sage Therapeutics, Inc. - Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
PayPal Unveils USD-Backed Stablecoin, Trucking Firm Yellow Corp Files For Bankruptcy, FDA Approves First Oral Treatment For Postpartum Depression: Today's Top Stories
Benzinga 
Via Benzinga
Why Sage Therapeutics Shares Are Sinking Monday
Sage Therapeutics Inc (NASDAQ: SAGE) shares are trading lower Monday after the company announced the FDA issued a Complete Response Letter (CRL) for one of the company's 
Via Benzinga
SOVO Stock Alert: Campbell Soup Is Buying Sovos Brands for $2.7 Billion
Sovos Brands (SOVO) stock is rising higher on Monday following news that Campbell Soup (CPB) is acquiring the Italian sauces company. 
Via InvestorPlace
Dow Jumps 250 Points; Tyson Foods Posts Downbeat Results
U.S. stocks were higher this morning, with the Dow Jones gaining more than 250 points on Monday. Following the market opening Monday, the Dow traded up 0.77% to 35,334.81 while the NASDAQ rose 0.42% to... 
Via Benzinga
What 10 Analyst Ratings Have To Say About Sage Therapeutics
 
Via Benzinga
Expert Ratings for Sage Therapeutics
 
Via Benzinga
Sage Therapeutics's Earnings Outlook
 
Via Benzinga
Why Is Sage Therapeutics (SAGE) Stock Down 48% Today?
Sage Therapeutics (SAGE) stock isn't doing the best on Monday after the FDA weighed in on the company's depression drug zuranolone. 
Via InvestorPlace
Why Sage Lost Half Its Value After The FDA Approved Its Depression Drug
The company gained approval for the first oral treatment for postpartum depression. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
FDA Approves Sage Therapeutics/Biogen's Zuranolone For One Type Of Depression, Rejects For Another
The FDA approved Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc's (NASDAQ: BIIB) Zurzuvae (zuranolone) 50 mg for adults with  
Via Benzinga
Wayfair To Rally Over 32%? Here Are 10 Other Analyst Forecasts For Monday
Needham raised the price target for MACOM Technology Solutions Holdings, Inc. (NASDAQ: MTSI) from $65 to $84. Needham analyst Quinn Bolton maintained a Buy rating. MACOM Technology shares rose 0.1% to... 
Via Benzinga
Sage Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Host Business Update Webcast and Announce Second Quarter Financial Results on Monday, August 7, 2023
From Sage Therapeutics, Inc.
Via Business Wire
FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
From Sage Therapeutics, Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2023
 
Via Benzinga
Why Sage Therapeutics Stock Is Tumbling Today
A partner's perceived lack of enthusiasm for an upcoming regulatory decision is spooking investors today. 
Via The Motley Fool
Why Universal Health Services Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Silicon Motion Technology Corporation (NASDAQ: SIMO) shares climbed 78.9% to $93.40 following a report suggesting China approval of the company's Maxlinear merger. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Sage Therapeutics to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Present at Upcoming May Investor Conferences
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics Announces First Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Report First Quarter 2023 Financial Results on Tuesday, May 2, 2023
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Present at the Stifel 2023 CNS Days
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics Appoints Jessica Federer to Board of Directors
From Sage Therapeutics, Inc.
Via Business Wire
Analyst Creates Bullish Pitch For Sage Therapeutics Around Greater Enthusiasm For Its Depression Drug, Zuranolone
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 13, 2023
 
Via Benzinga
Why Bank Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Provention Bio, Inc. (NASDAQ: PRVB) shares jumped 250.8% to $23.50 after Sanofi announced it will acquire the company for $25 per share in cash. 
Via Benzinga
Illumina, Seagen And Other Big Stocks Moving Higher On Monday
U.S. stocks traded slightly lower, with the Nasdaq Composite dropping around 0.2% on Monday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.